Cognition Therapeutics Stock EBITDA
| CGTX Stock | USD 0.43 0.01 2.27% |
Cognition Therapeutics fundamentals help investors to digest information that contributes to Cognition Therapeutics' financial success or failures. It also enables traders to predict the movement of Cognition Stock. The fundamental analysis module provides a way to measure Cognition Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cognition Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | -25.5 M | -24.2 M |
Cognition | EBITDA |
Cognition Therapeutics Company EBITDA Analysis
Cognition Therapeutics' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Cognition Therapeutics EBITDA | (25.51 M) |
Most of Cognition Therapeutics' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cognition Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cognition EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Cognition Therapeutics is extremely important. It helps to project a fair market value of Cognition Stock properly, considering its historical fundamentals such as EBITDA. Since Cognition Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cognition Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cognition Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Cognition Ebitda
According to the company disclosure, Cognition Therapeutics reported earnings before interest,tax, depreciation and amortization of (25.51 Million). This is 102.91% lower than that of the Biotechnology sector and 125.47% lower than that of the Health Care industry. The ebitda for all United States stocks is 100.65% higher than that of the company.
Cognition EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cognition Therapeutics' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cognition Therapeutics could also be used in its relative valuation, which is a method of valuing Cognition Therapeutics by comparing valuation metrics of similar companies.Cognition Therapeutics is currently under evaluation in ebitda category among its peers.
Cognition Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Cognition Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Cognition Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Cognition Therapeutics' value.| Shares | Renaissance Technologies Corp | 2024-09-30 | 88.7 K | Corsair Capital Management Llc | 2024-06-30 | 77.4 K | Bridgeway Capital Management, Llc | 2024-09-30 | 76.7 K | State Street Corp | 2024-06-30 | 62.8 K | Texas Capital Bank Wealth Management Services Inc | 2024-06-30 | 55.4 K | Fca Corp | 2024-09-30 | 51.5 K | Circle Wealth Management, Llc | 2024-09-30 | 48.8 K | Northern Trust Corp | 2024-09-30 | 47.5 K | Castle Wealth Management Llc | 2024-09-30 | 43.4 K | Vanguard Group Inc | 2024-09-30 | 1.2 M | Alyeska Investment Group, L.p. | 2024-09-30 | 500 K |
Cognition Fundamentals
| Return On Equity | -1.08 | ||||
| Return On Asset | -0.94 | ||||
| Current Valuation | (3.66 M) | ||||
| Shares Outstanding | 41.55 M | ||||
| Shares Owned By Insiders | 0.54 % | ||||
| Shares Owned By Institutions | 24.53 % | ||||
| Number Of Shares Shorted | 815.7 K | ||||
| Price To Book | 1.23 X | ||||
| EBITDA | (25.51 M) | ||||
| Net Income | (25.79 M) | ||||
| Cash And Equivalents | 46.61 M | ||||
| Cash Per Share | 1.94 X | ||||
| Total Debt | 1.24 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 4.20 X | ||||
| Book Value Per Share | 0.76 X | ||||
| Cash Flow From Operations | (16.02 M) | ||||
| Short Ratio | 1.07 X | ||||
| Earnings Per Share | (0.96) X | ||||
| Target Price | 6.2 | ||||
| Number Of Employees | 25 | ||||
| Beta | 1.34 | ||||
| Market Capitalization | 17.77 M | ||||
| Total Asset | 35.16 M | ||||
| Retained Earnings | (141.19 M) | ||||
| Working Capital | 24.05 M | ||||
| Net Asset | 35.16 M |
About Cognition Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cognition Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cognition Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cognition Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Cognition Stock Analysis
When running Cognition Therapeutics' price analysis, check to measure Cognition Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cognition Therapeutics is operating at the current time. Most of Cognition Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cognition Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cognition Therapeutics' price. Additionally, you may evaluate how the addition of Cognition Therapeutics to your portfolios can decrease your overall portfolio volatility.